Background: Dried blood spot (DBS) is a practical sampling strategy for pharmacokinetic studies in neonates. The utility of DBS to determine the population pharmacokinetics (pop-PK) of ampicillin, as well as accuracy versus plasma samples, was evaluated.
INTRODUCTION
One of the most inherent challenges of pediatric drug studies encompasses the ethics and logistics of blood sampling, in terms of number and volume. 1 Opportunistic study designs capitalize on standard-of-care procedures to minimize the risk to enhance parental consent and curtail research-related costs. These designs have been successfully used to enhance the dosing of antimicrobial agents in pediatrics, including neonates. [2] [3] [4] [5] [6] Microsampling is a cutting-edge technique that fosters an ethical approach to pediatric research, especially in neonates where the ability to ascertain a complete pharmacokinetics (PK) profile of the drug is constrained by blood volume and sampling frequency. Dried blood spot (DBS) is a microsampling method that measures concentrations in whole blood and uses an ultra-low volume to evaluate the PK of drugs. 7 As a minimally invasive alternative to venipuncture, the drops of whole blood can be easily obtained from a finger-or heel-stick with minimal requirement for training, therefore facilitating serial sampling for PK studies. 8 The DBS sampling strategy also eliminates the need for centrifugation or freezing of samples, thereby making the requirements for storage and shipment straightforward and less expensive. 8, 9 Furthermore, the Centers for Disease Control and Prevention reports that shipping DBS samples does not represent an occupational risk of exposure. 10 The practicality and convenience of DBS, as compared to traditional plasma sampling, makes this approach useful for research purposes and has been evaluated in neonates. [11] [12] [13] We designed this study testing the utility and accuracy of DBS versus plasma for determining the population PK (pop-PK) of ampicillin with the ultimate goal of expanding the literature on DBS sampling to potentially enhance its utility in the near future.
Ampicillin is one of the most commonly administered medications in the neonatal intensive care unit for early-onset sepsis and bacterial meningitis, so ampicillin was used as a probe drug to evaluate the utility of DBS sampling. Using an opportunistic study design with population-based PK modeling, our study objectives were to (1) characterize the in vivo relationship between CONC Plasma and CONC DBS , (2) develop and evaluate a transformation equation that accurately calculates estimated CONC Plasma (eCONC Plasma ) using CONC DBS , and (3) evaluate the accuracy of the DBS sampling strategy using pop-PK.
MATERIALS AND METHODS

Study Design
This prospective, multicenter (N = 7) trial was conducted under the PK of Understudied Drugs Administered to Children per Standard of Care (POPS III; protocol NICHD-HHSN27500027) by the Pediatric Trials Network (PTN). The data presented here were compiled from neonates receiving ampicillin. The protocol was reviewed and approved by the institutional review board of each participating institution.
Details of our methodology have been previously published. 5 Briefly, participating sites were encouraged to collect biological samples opportunistically; therefore, laboratory [including PK and serum creatinine (SCR)] samples were obtained at the time of clinical laboratory evaluations per standard of care. The plasma and DBS PK samples were obtained in pairs. For plasma samples, at least 200 mL (up to ;2000 mL) of whole blood was collected in an ethylenediaminetetraacetic acid (EDTA)-containing tube and separated by centrifugation at 2000g for 10 minutes at 48C. For DBS samples, blood was aliquoted from EDTA before centrifugation and 30 mL was spotted on FTA DMPK-C white cards from GE Healthcare Bio-Sciences (Pittsburgh, PA). Both plasma and DBS samples were stored frozen at #708C and shipped on dry ice until ampicillin concentrations were determined at the central laboratory. The imputation approach for SCR matched the closest record based on date and time. 5 
Bioanalytical Assay
Validated bioanalytical high-performance liquid chromatography with tandem mass spectrometric (HPLC-MS/ MS) assays were used to measure the CONC Plasma and CONC DBS at the PTN central laboratories OpAns Laboratory (Durham, NC) and Frontage Lab (Exton, PA), respectively. The validated range and limit of quantification of plasma method have been previously published. 5 For CONC DBS , ampicillin was extracted by protein precipitation from DBS samples using 0.5% formic acid in purified water. Reversedphase HPLC separation was achieved with a Hyperclone BDS column (150 · 2.0 mm, 5 mm). MS/MS detection was set at mass transitions of m/z 350.5/160.1 for ampicillin in Turbo Ion spray (TIS) positive mode. The validation range for the assay was 0.05-50.0 mcg/mL. Quality control samples included the following nominal concentrations: 0.15, 5.0, 37.5, and 150 mcg/mL. The lower limit of quantification was 0.05 mcg/mL. Accuracy and precision was assessed using 5 determinations at theoretical levels and were within the Food and Drug Administration bioanalytical assay validation criteria (eg, 615%). All sample runs for the study met acceptance criteria.
DBS Analysis and Transformation Methods
Correlation analysis was performed to determine the association between CONC Plasma and CONC DBS . Different transformation methods (including ratio, linear regression, and log-linear regression) were used to derive a formula to calculate eCONC Plasma using CONC DBS . The Bland-Altman plot of the ratio of CONC DBS (and eCONC Plasma ) to CON-C Plasma was computed and plotted against mean combined concentrations, together with the 95% confidence interval (CI) of the mean ratio. 14 Except for the PK modeling, all analyses were performed using SPSS PASW 22 (SPSS, Inc, Chicago, IL).
Population PK Analysis
Using measured CONC Plasma from a small subset of subjects evaluated in a previous study, 5 data were fitted to a 1-compartment model (ADVAN1 TRANS2) with the First Order Conditional Estimation method with ETA-EPS interaction (FOCE-I) and Bayesian post hoc estimation in NON-MEM 7.2 (Icon, Dublin, Ireland). 5 To explore differences in population PK parameter estimates with plasma, DBS, and estimated plasma concentrations, we ran the same model 3 times using each concentration matrix. The bias in concentrations and pop-PK parameter estimates (Y) were assessed 
RESULTS
A total of 29 CONC DBS were sampled at the same time as CONC Plasma from 18 subjects, except for 1 CONC DBS that was obtained 19 minutes before CONC Plasma . The demographic characteristics are summarized in Table 1 .
DBS Analysis and Transformation Methods
Using the 29 paired samples, a strong correlation between CONC Plasma and CONC DBS was observed (Spearman rho = 0.97, P , 0.001, Fig. 1A ). The slopes of the 90% fit loess (with Epanechnikov kernel smoothing) trend lines for the CONC Plasma and CONC DBS were similar, especially at #6-hour time points. Different transformation methods were evaluated to derive a formula to calculate eCONC Plasma using CONC DBS data ( Table 2) . Using the simple linear regression method, CONC Plasma was a significant predictor of CONC DBS [where (CONC DBS ) = 3.223 + 0.51 · (CONC plasma ); r 2 = 0.902, analysis of variance P , 0.001; Fig. 1B ]. Approximately 90% of the variability in CONC DBS was explained by CONC Plasma . In addition, the mean eCONC Plasma was similar to CONC Plasma (101.4 6 83.0 versus 101.4 6 78.8, respectively, P = 1). Further statistical and PK analyses were conducted using eCONC Plasma derived by this linear regression method.
Bland-Altman analysis revealed that the geometric mean ampicillin concentration ratios between CONC DBS and CONC Plasma , as well as eCONC Plasma and CONC Plasma , were 0.56 (95% CI, 0.31-0.89) and 0.88 (95% CI, 0.31-1.58), respectively. The ratio of eCONC Plasma /CONC Plasma was significantly higher than that of CONC DBS /CONC Plasma (Wilcoxon signed-rank test, n = 29, P , 0.001). One CONC DBS fell outside the 95% CI ( Fig. 2A) . All eCONC Plasma were within the 95% limits of agreement (Fig. 2B) .
Population PK Analysis
A total of 35 plasma and 30 DBS samples from 18 subjects were included in the pop-PK analysis. All CON-C Plasma and CONC DBS data were above the lower limit of quantification. The median (range) time after last dose of PK sampling, CONC Plasma , and CONC DBS data was 5.7 (0.3-14.3) hours, 86 (7-293) mcg/mL, and 47 (4-158) mcg/ mL, respectively. The number of CONC Plasma measured from the beginning of infusion to 1.0 hours was 7 (20%), 1.1-2.0 hours was 3 (9%), 2.1-5.0 hours was 7 (20%), 5.1-8.0 hours was 5 (14%), and .8 hours was 13 (37%).
The final pop-PK model, derived from CONC Plasma using FOCE-I with combination residual error, was applied to the CONC DBS and eCONC Plasma matrices ( Table 3 ). The median bias (interquartile range) of the CONC DBS was 244% (251 to 234), which improved to 211% (256 to 14) when CONC DBS was transformed to eCONC Plasma . Using the final pop-PK model, the median bias of clearance and individual predicted concentrations improved by 62% and 35%, respectively, when transformed DBS concentrations were used (Table 4) . 
DISCUSSION
In our previously published study, a broad age spectrum of neonates was incorporated to enable the construct of a pop-PK model, reflecting developmental changes, that was subsequently used to simplify ampicillin dosing regimens. 5 Here, a subset of the data with paired DBS-plasma samples was used for comparative analyses using PK modeling. Although correlation analysis demonstrated strong association between CONC Plasma and CONC DBS , the bias exceeded .15%, demonstrating that bias was present. [14] [15] [16] Bias between plasma and DBS concentrations was expected based on in vitro data suggesting lack of ampicillin penetration into red blood cells. A similar phenomenon was observed with in vivo data as evidenced by the ratio of DBS to plasma concentrations. The differences between DBS (whole blood) and plasma could have been explained by evaluating the role of hematocrit in DBS concentrations. Nevertheless, a hematocrit correction was not performed because (1) in the context of an opportunistic study, there was no access to the closest hematocrit measured before PK sample collection; (2) of avoidance in evaluating the effect of individual differences in red blood cell penetration in these analyses; and (3) of the goal to explore a practical approach for DBS concentration management in PK analyses. Therefore, the focus was on the use of statistical models to transform DBS concentration data to plasma. Furthermore, the same observed bias is retained when either the pop-PK or statistical approach is used.
Based on eCONC Plasma , which was transformed to CONC DBS using linear regression, the ampicillin clearance and exposure improved to values similar to those obtained from observed CONC Plasma . Simple linear regression has been used in other clinical studies to transform DBS into estimated plasma concentrations. 13, 17 Alternatively, the ratio transformation method has been evaluated for antiepileptic drugs in children. 18 With ampicillin displaying a wide therapeutic index, fluctuations of drug concentrations within a reasonable margin should not affect efficacy and safety, which implies that the accuracy margin to use DBS (albeit transformed and not directly) to predict ampicillin exposure may be less restrictive. As a result, the use of DBS samples in this opportunistic study provided the in vivo relationship between whole blood and plasma concentrations of ampicillin and, more importantly, a practical approach for PK sampling to predict drug exposure. In addition, because hematocrit changes with age and was not incorporated in the linear regression, the transformation method to estimate eCONC Plasma is only applicable to neonates.
The DBS sampling approach has been studied for both research purposes (as in this study) and clinical use, including therapeutic drug monitoring and newborn screening for congenital metabolic diseases. Various antibiotics have been evaluated using DBS technology in pediatric research. [11] [12] [13] 19, 20 In clinical practice, the use of DBS as an alternative to plasma concentrations has been applied to drugs with a narrow 
Limitations
This study had several limitations. First, the small sample size and sparse sampling of both the CONC Plasma and CONC DBS data prevented the application of our published model, because of over-parameterization and large relative standard error. Second, the CONC Plasma and CONC DBS were assayed at different laboratories, which may have contributed to the variability. Finally, the DBS sampling technique requires uniform spot coverage on the card, rapid spot drying, and storage in low humidity. In the absence of these conditions, variability in CONC DBS may have been introduced.
More research studies are needed to explore and validate the DBS microsampling technique in PK studies for neonates and pediatrics, especially those who are critically ill, to augment the overall understanding of the altered pharmacokinetic properties resulting from maturation and severity of illness. 24 Furthermore, this sampling strategy should be studied for currently marketed and new drugs, especially those with a narrow therapeutic index if intended for integration into the clinical setting.
CONCLUSIONS
Ampicillin DBS concentrations were successfully used to estimate plasma concentrations in this pop-PK study in neonates. The practicality, convenience, and enhanced parental acceptance of DBS sampling, as compared to traditional plasma, makes this approach attractive for research and clinical use. 
